Impact of frequent hemodialysis on anemia management: results from the Frequent Hemodialysis Network (FHN) Trials.

ABSTRACT:

Background

The extent to which anemia management is facilitated by more frequent hemodialysis (HD) is controversial. We hypothesized as a preselected outcome that patients receiving HD six times (6×) compared with three times (3×) per week would require lower doses of erythropoietin-stimulating agents (ESA) and/or achieve higher blood hemoglobin (Hb) concentrations.

Methods

Subjects enrolled in the Frequent Hemodialysis Network (FHN) daily and nocturnal trials were studied. As the primary outcome for anemia, the dose of ESAs was recorded at 4-month intervals and the monthly dose of intravenous iron (IV Fe) was reported. Serum iron, transferrin saturation and ferritin were measured at baseline and then at 4-month intervals, whereas Hb concentration was measured monthly.

Re

SUBMITTER: Ornt DB 

PROVIDER: S-EPMC3707527 | biostudies-literature | 2013 Jul

REPOSITORIES: biostudies-literature